Testing a new tablet form of an experimental medicine
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests how well a new tablet version of an experimental medicine (VX-581) is absorbed by the body. It may help researchers find the best way to give this medicine in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 32 on the body mass index (BMI) scale. This is a way to check if your weight is healthy for your height.
- You must weigh more than 50 kilograms (about 110 pounds).
- You must be a nonsmoker or have quit smoking at least 3 months before the study starts.
- You must not have had a fever or any other short-term illness within 14 days before taking the study drug.
- You must not have any condition (like stomach or bowel problems) that could affect how your body absorbs the medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called VX-581 in healthy volunteers to see how safe it is and how the body handles it. It is an early-phase trial, so it helps determine the right dose for future studies.
This study tests a new investigational medicine called VX-272 in healthy volunteers. Researchers want to check its safety and how it moves through the body, so you would not have the condition the medicine is being developed for.
This study tests an experimental inhalable medicine called ARCT-032 for people with cystic fibrosis who cannot take or benefit enough from current CFTR modulators. The goal is to see if it safely improves lung function and quality of life.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.